NervGen Pharma (NGEN) Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
NGEN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NervGen Pharma Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$5.63 |
| 52 Week High | CA$6.30 |
| 52 Week Low | CA$1.50 |
| Beta | 0.76 |
| 1 Month Change | 24.56% |
| 3 Month Change | 83.99% |
| 1 Year Change | 179.40% |
| 3 Year Change | 265.58% |
| 5 Year Change | 196.32% |
| Change since IPO | 332.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| NGEN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.1% | -0.01% | -0.3% |
| 1Y | 179.4% | 30.2% | 15.4% |
Return vs Industry: NGEN exceeded the US Pharmaceuticals industry which returned 30.2% over the past year.
Return vs Market: NGEN exceeded the US Market which returned 15.4% over the past year.
Price Volatility
| NGEN volatility | |
|---|---|
| NGEN Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Adam Rogers | www.nervgen.com |
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
NervGen Pharma Corp. Fundamentals Summary
| NGEN fundamental statistics | |
|---|---|
| Market cap | US$439.03m |
| Earnings (TTM) | -US$18.38m |
| Revenue (TTM) | n/a |
Is NGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGEN income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$25.57m |
| Earnings | -CA$25.57m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/18 01:42 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NervGen Pharma Corp. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott McAuley | Paradigm Capital, Inc. |
| Michael Freeman | Raymond James Ltd. |
| Andre Uddin | Research Capital Corporation |